HC Wainwright & Co. Maintains Buy on Olema Pharmaceuticals, Raises Price Target to $22
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Emily Bodnar maintains a 'Buy' rating on Olema Pharmaceuticals and raises the price target from $17 to $22.
August 09, 2023 | 10:44 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Olema Pharmaceuticals' price target has been raised from $17 to $22 by HC Wainwright & Co. The firm maintains a 'Buy' rating on the stock.
The raised price target and maintained 'Buy' rating by HC Wainwright & Co. indicates a positive outlook for Olema Pharmaceuticals. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100